David Sinclair· PhD
Study @FASEBorg says the NAD-dependent enzyme Sirt1 mediates resveratrol's browning of fat cells & fat mobilization in mice, "suggesting the potential of Res in the treatment of obesity & metabolic disorders."
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
Study @FASEBorg says the NAD-dependent enzyme Sirt1 mediates resveratrol's browning of fat cells & fat mobilization in mice, "suggesting the potential of Res in the treatment of obesity & metabolic disorders."
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.